US FDA completes Kadu plant inspection without observations

Regulatory & Legal View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹1398.10

prior close

₹1432.10

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.6%+1.0% vs market

Pharmaceuticals peers, median of 152sector+0.2%+1.3% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Smallcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.3

15m

-0.5

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6+0.6+1.0+0.2+1.3

Next day

-2.0+0.3-2.3-0.5-1.6

-4.4-0.6-3.9-1.4-3.0

-2.3+0.3-2.6-0.9-1.4

-4.0+0.6-4.7-0.5-3.5

-3.5+0.4-4.0-0.9-2.7

-0.7+1.6-2.3+0.1-0.8

15d

-5.8+2.5-8.3+0.3-6.0

+1.7+0.1+1.7-2.1+3.9

+0.7-4.9+5.6-5.8+6.5

+6.9-5.3+12.3-9.0+15.9

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The US FDA inspected Emcure's manufacturing facility at Kadu in Surendranagar, Gujarat from October 6 to October 10, 2025. The inspection concluded without any observations, and no regulatory action was reported.

Likely market impact

The clean inspection reduces near-term regulatory uncertainty around the Kadu plant and may support positive investor sentiment.